Sam Lidman: Daily

Hitting $2M ARR, VMEG AI challenges the 'black box' status quo, offering enterprises transparent control over global video localization and brand integrity.

Beyond a simple tech deal, Aritzia's partnership with Adyen reveals a masterclass in building permanence by unifying its luxury brand experience.

Lycia Therapeutics' oversubscribed $75M Series D validates its unique LYTAC platform, which aims to treat autoimmune diseases by destroying harmful proteins.

Professor Jason Chin’s Heinrich Wieland Prize signals a new era. His work in synthetic biology is enabling Constructive Bio to forge a new class of drugs.

Verano's upcoming Q2 report is a key indicator for the cannabis sector. We look at the strategic moves, from stock splits to rescheduling, setting the stage.

Dubai is making a calculated play in Berlin, using GITEX AI Europe not just to showcase its tech but to architect a resilient, high-performance digital future.

Kadima Neuropsychiatry sues NRx Pharma, alleging deceit in a failed acquisition. The case reveals the high stakes of corporate integrity and financial truth.

In Rochester's booming cannabis scene, knowledge is the new currency. A look at how expert-led education is building a resilient, professional industry.

Facial scans replace your ID at the airport via Google Wallet. Sam Lidman explores the trade-offs between seamless travel and the new architecture of identity.

A St. Louis orthopedic group is using tech to fix the broken workers' comp system. Is this the future of specialized healthcare access for employers?

A new media deal signals Perfect Game’s evolution from a scouting service to a content giant, reshaping talent discovery and value creation in youth sports.

As states mandate online age checks, a new solution from L8P8 claims to verify users without storing personal data. Is this the key to child safety?

A strategic partnership between IMU Biosciences and Waters Corp. aims to pair AI with advanced hardware, creating a high-definition map of our immune system.

Imbria's ninerafaxstat gains FDA Orphan Drug status for nHCM, a rare heart condition. This strategic win pits its unique metabolic approach against rivals.

A 27% stock plunge and a class action lawsuit have hit Phreesia. But the real story lies in the shifting sands of pharma marketing and SaaS growth promises.

As EOFY pressure mounts, one Aussie tech firm offers more than a discount—it offers a digital nervous system for an industry running on manual fumes.

A new survey reveals half of parents find dinner their most stressful daily event. This isn't just a social trend; it's a market signal driving a revolution.

In two years, XERF has dominated the skin tightening market. We explore the strategy, tech, and cultural shift behind its meteoric, resilient rise.

As autonomous AI agents multiply, creating chaos and risk, a new class of governance is emerging. A key partnership shows how enterprises can regain control.

A new partnership is setting a new standard for due diligence in private lending, leveraging AI to slash risk, eliminate errors, and build resilient loan books.